Assessing the Long and Short View of pSivida Corp.
pSivida Corp. (NASDAQ:PSDV) is not a proof-of-concept stage biopharmaceutical company, but is a developer of a proven, sustained release drug delivery system. pSivida already has two approved products, Retisert partnered with Bausch & Lomb for the treatment of chronic noninfectious uveitis, and Iluvien partnered with Alimera Sciences (NASDAQ:ALIM) in the treatment of Diabetic Macular Edema (DME). Iluvien is already approved in 6 EU countries and it is expected to have an FDA decision by 4Q14. pSivida is entitled to 20% royalties of both products and is developing Medidur, which is their first full commercial rights product for posterior Uveitis in Phase III trials. Importantly, pSivida ...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|